Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
NCT ID: NCT01741597
Last Updated: 2014-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To explore the ability of iRGD (tumor-homing peptide iRGD) to elicit changes in metastatic breast cancer vascular permeability as measured by dynamic contrast enhanced (DCE) MRI.
II. To evaluate the pharmacokinetics of iRGD. III. To explore the safety of iRGD.
SECONDARY OBJECTIVES:
I. To explore changes in water diffusion status in tumors due to iRGD as measured by diffusion-weighted (DWI) MRI.
II. To explore the ability of iRGD to elicit changes in primary pancreatic cancer vascular permeability as measured by dynamic contrast enhanced (DCE) MRI.
III. To explore changes in water diffusion status in primary pancreatic cancer due to iRGD as measured by DWI-MRI.
OUTLINE:
Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
After completion of study treatment, patients are followed up for 15 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (DCE-MRI, tumor-homing peptide iRGD)
Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI
pharmacological study
Correlative studies
tumor-homing peptide iRGD
Undergo tumor-homing peptide iRGD DCE-MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI
pharmacological study
Correlative studies
tumor-homing peptide iRGD
Undergo tumor-homing peptide iRGD DCE-MRI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Women of child-bearing potential must have a negative serum pregnancy test within 7 days of the first DCE-MRI and must have agreed to use an effective contraceptive method; the effects of iRGD on the developing fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
* Patient must have a measurable lesion at least 2 cm in size amenable to DCE-MRI study as determined by Radiology
* Computed tomography (CT)/MRI scan must be obtained within 3 weeks prior to study entry
* Absolute neutrophil count \>= 1,500/mcl
* Platelet count \>= 100,000/mcl
* Creatinine =\< 1.3 mg/dl or a measured creatinine clearance \>= 60 cc/min
* Bilirubin =\< 1.5 mg/dl
* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 2.5 times the upper limit of normal for patients with liver metastases; patients without liver metastasis should have ALT and AST no greater than 1.5 times the upper limit of normal
* Patients currently being treated for severe infections or who are recovering from major surgery or other intercurrent illnesses are ineligible until recovery is deemed complete by the investigator
* All subjects must have the ability to understand and the willingness to sign a written informed consent
* Patients with grade 2 or higher toxicity due to previous chemotherapy; all toxicities should recover to grade 0 or 1 prior to day 1
Exclusion Criteria
* Patients with any grade electrolyte abnormalities that are unable to be corrected by day 1
* Patients with a history of previous reaction to IV contrast
* Impaired cardiac function including any one of the following:
* Complete left bundle branch block or use of a permanent cardiac pacemaker
* Congenital long QT syndrome
* Presence of ventricular tachyarrhythmias
* Clinically significant resting bradycardia (\< 50 beats per minute)
* Corrected Fridericia's QT interval (QTcF) \> 450 msec on screening electrocardiogram (ECG)
* Right bundle branch block + left anterior hemiblock (bifascicular block)
* Presence of atrial fibrillation
* Previous history angina pectoris or acute myocardial infarction (MI) within 6 months
* Congestive heart failure (New York Heart Association functional classification III-IV)
* Uncontrolled hypertension (mmHg \> 140 systolic or \> 90 diastolic)
* Brain or leptomeningeal metastases
* Patients with an active, bleeding diathesis or requiring therapeutic anticoagulation
* Patients receiving bevacizumab within 3 months of study entry
* Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
* Patients should not have any uncontrolled illness including ongoing or active infection
* Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to iRGD
* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent Chung
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-02449
Identifier Type: REGISTRY
Identifier Source: secondary_id
12228
Identifier Type: -
Identifier Source: org_study_id